• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Australian regulators propose changes to IVD oversight plan

Australian regulators propose changes to IVD oversight plan

May 16, 2013 By MassDevice Contributors Network

Global Medicine

By Stewart Eisenhart, Emergo Group

Australia’s Therapeutic Goods Administration (TGA) has published proposed changes to upcoming in vitro diagnostic (IVD) regulations for comment ahead of a proposed final implementation date of July 2014.

High-level components of the new Australian IVD regulatory scheme include:

  • A four-tier, risk-based classification system (Class 1, 2, 3 and 4)
  • All commercial IVDs must be included in the Australian Register of Therapeutic Goods (ARTG)
  • All IVD must meet Essential Principles regarding quality, safety and performance
  • Manufacturers of IVDs must apply conformity assessments to demonstrate compliance with Essential Principles
  • Post-market monitoring processes

Proposed changes to the TGA IVD regulation

First, the TGA has proposed a staged transition to the new IVD regulatory system to give firms more time to ensure compliance. Manufacturers would have to submit conformity assessment certification applications to the TGA by 30 June 2014; applications for inclusion in the ARTG would have to be submitted by 30 June 2015. Alternately, manufacturers would have to apply to the ARTG by 30 June 2014.

Second, the TGA would align conformity assessments for some Class IV IVDs used by laboratories for internal testing more closely with requirements for commercial IVDs.

Third, the TGA would be authorized to undertake performance evaluations of Class IV IVDs submitted for design examination. These evaluations would be determined based on issues such as level of risk, intended use and manufacturer’s performance claims.  

Fourth, Australian regulators would redefine the definition of a medical device to include IVD tests for genetic predispositions or susceptibility to diseases. Such tests currently fall under “other therapeutic goods” in Australia.

The TGA has set a deadline of 31 May 2013 for accepting comments on its proposals. 

Stewart Eisenhart covers medical device regulatory affairs for Emergo Group.

Filed Under: News Well Tagged With: Australia Therapeutic Goods Administration, Emergo Group, Exports

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy